<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018264</url>
  </required_header>
  <id_info>
    <org_study_id>URGE-PD</org_study_id>
    <nct_id>NCT01018264</nct_id>
  </id_info>
  <brief_title>Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease</brief_title>
  <acronym>URGE-PD</acronym>
  <official_title>URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing
      symptoms of overactive bladder in Parkinson's disease (PD) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Micturations Per 24 Hour Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective of this study is to measure the efficacy of solifenacin succinate (VESIcare) in reducing the mean number of micturitions per 24 hour period in Parkinson's disease (PD) patients as measured by voiding diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Urinary Incontinence Episodes Per 24 Hour Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>This scale it the mean number of urinary incontinence episodes per 24 hour period, as assessed by a 3-day bladder diary. The goal is to examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Total</measure>
    <time_frame>12 weeks</time_frame>
    <description>To examine the effect of solifenacin succinate (VESIcare) on Parkinson's disease severity. The UPDRS total score ranges from 0 (no disability) to 199 (total disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Quality of Life Scale (PDQOL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This scale is used to assess quality of life in Parkinson's Disease patients. Parkinson's disease quality of life scale has a possible point range from 37 (worst outcome) to 185 (best outcome). The goal of this outcome measure is to examine the effect of solifenacin succinate (VESIcare) on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Nocturia Episodes Per 24 Hour Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>To examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Overactive Bladder in Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>solifenacin succinate (VESIcare)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin succinate (VESIcare)</intervention_name>
    <description>up to 10mg every day orally</description>
    <arm_group_label>solifenacin succinate (VESIcare)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients with idiopathic PD according to the UK Parkinson's Disease Society Brain
             Bank Clinical Diagnosis Criteria.

          2. Age 40 years to 80 years.

          3. Stable dose of antiparkinsonian medication 4 weeks prior to study entry.

          4. Patients must score 1.0 to 3.0 on the Modified Hoehn and Yahr scale.

          5. Women of child-bearing potential must use a reliable method of contraception.

          6. Must be experiencing symptoms of overactive bladder according to the ICS definition of
             a minimum voiding 8 or more times/24 hours and a daily average of at least 1 episode
             of urgency and/or urinary incontinence (urge incontinence predominately as measured by
             3IQ diary) per 24 hours during a 3-day micturition diary period. Patients must have
             documentation of OAB within the last 6 months.

          7. The patient must have evidence of PSA less than or equal to 4 (males only) within the
             last 12 months (obtained from primary care physician).

          8. The patient must have had a bladder scan within six months of the screening visit.
             This scan uses ultrasound technology to measure residual fluid levels in the bladder
             after urination. This scan must document post void residual of 200 mls or less. A
             bladder scan printout or a note documenting these findings must be provided before
             baseline.

          9. Clearance from the patient's internist or primary care health provider who has
             examined the patient within the last 6 months.

        Exclusion Criteria:

          1. Any illness that in the investigator's opinion preclude participation in this study.

          2. Pregnancy or lactation.

          3. Concurrent participation in another clinical study.

          4. Dementia or other psychiatric illness that prevents the patient from giving informed
             consent (Mini Mental Status Exam scores less than 27).

          5. Legal incapacity or limited legal capacity.

          6. History of prostate cancer or Transurethral resection of the prostate (TURP) (males
             only).

          7. Presence of severe renal disease. BUN 50% greater than normal (normal BUN levels
             should be within a range of 5 to 20 mg/ d L and creatinine between .7 and 1.4 mg/ d
             L). Labs within the past 12 months will be requested from the patient's health care
             provider or urologist. If labs are not available within this time-frame or if results
             are abnormal, labs will be obtained as part of the screening visit.

          8. Presence of major hepatic impairment (cirrhosis, viral hepatitis, nonalcoholic
             steatohepatitis, Wilson's disease, or Hemochromotosis).

          9. Currently taking ketaconazole (anti-fungal) or any CYP3A4 inhibitor such as
             itraconazole, ritonavir, nelfinavir, clarithromycin, or nefazadone.

         10. Any history of bladder outflow obstruction or gastrointestinal obstructive disorders.

         11. History of narrow angle glaucoma.

         12. Patients who have undergone pelvic radiation at any time.

         13. Currently taking any of the following medications:

               -  Antiarrhythmics: flecainide (Almarytm, Apocard, Ecrinal, Fl√©caine), digoxin
                  (Lanoxin, Digitek, Lanoxicaps)

               -  Antipsychotics: thioridazine (Mellaril, Novorizadine, Thioril)

               -  Tricyclic anti-depressants: amitriptyline (Elavil, Tryptanol, Endep, Elatrol,
                  Tryptizol, Trepiline, Laroxyl), amoxapine (Asendin, Asendis, Defanyl, Demolox,
                  Moxadil), clomipramine (Anafranil), desipramine (Norpramin, Pertofrane),
                  imipramine (Antideprin, Deprenil, Deprimin, Deprinol, Depsonil, Dynaprin,
                  Eupramin, Imipramil, Irmin, Janimine, Melipramin, Surplix, Tofranil),
                  nortriptyline (Aventyl, Pamelor, Nortrilen), protriptyline (Vivactil),
                  trimipramine (Stangyl, Surmontil, Rhotrimine)

               -  Psychotropics: doxepin (Aponal, Adapine, Sinquan, Sinequan)

               -  Anticholinergics/Antispasmodics: trihexyphenidyl (Artane, Aparkan), benztropine
                  (Cogentin), oxybutynin (Ditropan, Ditropan XL, Lyrinel XL, Oxytrol), darifenacin
                  (Enablex), emepronium, flavoxate (Urispas), meladrazine, propiverine, solifenacin
                  (Vesicare), tolterodine (Detrol, Detrol LA), trospium (Sanctura)

               -  Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI): duloxetine
                  (Cymbalta, Yentreve), Venlafaxine (Effexor, Effexor XR)

               -  Arylalkylamines: pseudoephedrine (Sudafed)

               -  Anti-androgen: bicalutamide (Casodex, Cosudex, Calutide, Kalumid), finasteride
                  (Proscar, Propecia, Fincar, Finpecia, Finax, Finast, Finara, Finalo, Prosteride,
                  Gefina, Finasterid IVAX), dutasteride (Avodart, Avidart, Avolve, Duagen, Dutas,
                  Dutagen, Duprost), Zoladex (goserelin acetate), Eulexin (flutamide), Lupron
                  (leuprolide acetate)

               -  Antihypertensives: prazosin (Minipress, Vasoflex, Hypovase)

               -  Estrogens (Menest, Premarin, Premarin IV)

               -  Acetylcholinesterase inhibitors (rivastigmine (Exelon), galantamine, (Reminyl,
                  donepezil (Aricept), Tacrine.

               -  Memantine (Namenda)

         14. Urinary obstruction in male PD patients as diagnosed by a urologist

         15. Active urinary tract infection.

         16. Patients with a history of chronic severe constipation (by self report)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <results_first_submitted>April 15, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2015</results_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Theresa Zesiewicz</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Overactive bladder</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Urinary frequency</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Solifenacin Succinate (VESIcare)</title>
          <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Solifenacin Succinate (VESIcare)</title>
          <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="6.6"/>
                    <measurement group_id="B2" value="66.5" spread="9.3"/>
                    <measurement group_id="B3" value="66.96" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) ADL subsection (mean)</title>
          <description>This subscale of the UPDRS measures activities of daily living. Points can range from 0-52 with 0 being better outcomes and 52 being a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.50" spread="5.40"/>
                    <measurement group_id="B2" value="11.23" spread="4.76"/>
                    <measurement group_id="B3" value="10.48" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Motor subsection (Part III)</title>
          <description>This is part III of the UPDRS scale. It measures motor function in PD patients. Scores range from 0 to 108, with a score of 0 being a better outcome and 108 being a worse outcome.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.60" spread="4.38"/>
                    <measurement group_id="B2" value="14.69" spread="5.19"/>
                    <measurement group_id="B3" value="13.78" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total score</title>
          <description>The UPDRS is a rating tool to follow the longitudinal course of Parkinson's Disease. It is made up of: Part 1- Mentation, Behavior, and Mood; Part 2- Activities of Daily Living (ADL); Part 3 - Motor function; and Part IV - Complications. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 represents the worst (total disability), 0 =no disability. To get the total score you sum up each subsection score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.00" spread="9.67"/>
                    <measurement group_id="B2" value="25.08" spread="11.93"/>
                    <measurement group_id="B3" value="24.61" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parkinson's Disease Quality of Life (PDQOL) total score</title>
          <description>Parkinson's disease quality of life scale has a possible point range from 37 (worst outcome) to 185 (best outcome).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.10" spread="19.96"/>
                    <measurement group_id="B2" value="115.31" spread="10.68"/>
                    <measurement group_id="B3" value="119.13" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn &amp; Yahr stage</title>
          <description>Stage 1: Unilateral disease. (Better outcome) Stage 1.5: Unilateral plus axial involvement. Stage 2: Bilateral disease, without impairment of balance. Stage 2.5: Mild bilateral disease, with recovery on pull test. Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent. (Worst Outcome)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence Quality of Life scale (IQOL)</title>
          <description>The Incontinence Quality of Life scale has a possible range of 22 (worst outcome) to 110 (best outcome) total points.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.00" spread="20.03"/>
                    <measurement group_id="B2" value="75.92" spread="18.87"/>
                    <measurement group_id="B3" value="76.83" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bladder diary: # micturations</title>
          <description>This is the mean number of micturations per 24 hour period as recorded on a 3-day bladder diary</description>
          <units>Micturation episodes per 24 hour period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.03" spread="2.21"/>
                    <measurement group_id="B2" value="9.23" spread="3.31"/>
                    <measurement group_id="B3" value="9.14" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bladder diary: # leaks</title>
          <description>This is the mean number of leaks as recorded on a 3-day bladder diary.</description>
          <units>Number of leaks per 24-hour period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.33" spread="2.45"/>
                    <measurement group_id="B2" value="1.72" spread="1.23"/>
                    <measurement group_id="B3" value="1.55" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bladder diary: # nocturia episodes</title>
          <description>This is the mean number of nocturia episodes as recorded on a 3-day bladder diary.</description>
          <units>Number of nocturia episodes per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.23" spread="1.69"/>
                    <measurement group_id="B2" value="1.90" spread="1.09"/>
                    <measurement group_id="B3" value="2.04" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient perception of Bladder Condition (PBC/PPBC)</title>
          <description>The PBC/PPBC is a single-item global measure for patients with overactive bladder.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Causes me (some) moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causes me severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causes me many severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Perception of Intensity of Urgency Scale (PPIUS)</title>
          <description>The PPIUS is a scale to assess patient's perception of their level of urgency. Mild urgency = better outcome; Severe urgency = worse outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild Urgency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Urgency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Urgency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Micturations Per 24 Hour Period</title>
        <description>The primary objective of this study is to measure the efficacy of solifenacin succinate (VESIcare) in reducing the mean number of micturitions per 24 hour period in Parkinson‚Äôs disease (PD) patients as measured by voiding diaries.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin Succinate (VESIcare)</title>
            <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Micturations Per 24 Hour Period</title>
          <description>The primary objective of this study is to measure the efficacy of solifenacin succinate (VESIcare) in reducing the mean number of micturitions per 24 hour period in Parkinson‚Äôs disease (PD) patients as measured by voiding diaries.</description>
          <units>Number of micturations per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="2.18"/>
                    <measurement group_id="O2" value="9.19" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="3.36"/>
                    <measurement group_id="O2" value="8.94" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline value</method_desc>
            <param_type>Effect size</param_type>
            <param_value>0.20</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>This represents the effect size between solifenacin and placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Urinary Incontinence Episodes Per 24 Hour Period</title>
        <description>This scale it the mean number of urinary incontinence episodes per 24 hour period, as assessed by a 3-day bladder diary. The goal is to examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin Succinate (VESIcare)</title>
            <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urinary Incontinence Episodes Per 24 Hour Period</title>
          <description>This scale it the mean number of urinary incontinence episodes per 24 hour period, as assessed by a 3-day bladder diary. The goal is to examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity.</description>
          <units>Number of incontinence episodes/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="2.56"/>
                    <measurement group_id="O2" value="1.78" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.31"/>
                    <measurement group_id="O2" value="1.61" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
            <param_type>Effect size</param_type>
            <param_value>0.53</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total</title>
        <description>To examine the effect of solifenacin succinate (VESIcare) on Parkinson's disease severity. The UPDRS total score ranges from 0 (no disability) to 199 (total disability).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin Succinate (VESIcare)</title>
            <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total</title>
          <description>To examine the effect of solifenacin succinate (VESIcare) on Parkinson's disease severity. The UPDRS total score ranges from 0 (no disability) to 199 (total disability).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="9.70"/>
                    <measurement group_id="O2" value="25.67" spread="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" spread="9.59"/>
                    <measurement group_id="O2" value="25.75" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANCOVA</method>
            <param_type>Effect size</param_type>
            <param_value>0.35</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Quality of Life Scale (PDQOL)</title>
        <description>This scale is used to assess quality of life in Parkinson's Disease patients. Parkinson's disease quality of life scale has a possible point range from 37 (worst outcome) to 185 (best outcome). The goal of this outcome measure is to examine the effect of solifenacin succinate (VESIcare) on quality of life.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin Succinate (VESIcare)</title>
            <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Quality of Life Scale (PDQOL)</title>
          <description>This scale is used to assess quality of life in Parkinson's Disease patients. Parkinson's disease quality of life scale has a possible point range from 37 (worst outcome) to 185 (best outcome). The goal of this outcome measure is to examine the effect of solifenacin succinate (VESIcare) on quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.00" spread="20.95"/>
                    <measurement group_id="O2" value="114.50" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.00" spread="26.42"/>
                    <measurement group_id="O2" value="112.92" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>ANCOVA</method>
            <param_type>Effect size</param_type>
            <param_value>0.27</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Nocturia Episodes Per 24 Hour Period</title>
        <description>To examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin Succinate (VESIcare)</title>
            <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nocturia Episodes Per 24 Hour Period</title>
          <description>To examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity</description>
          <units>Number of nocturia episodes per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="1.59"/>
                    <measurement group_id="O2" value="1.92" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="1.96"/>
                    <measurement group_id="O2" value="1.78" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>ANCOVA</method>
            <param_type>Effect size</param_type>
            <param_value>0.11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Solifenacin Succinate (VESIcare)</title>
          <description>solifenacin succinate (VESIcare): up to 10mg every day orally</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa Zesiewicz, MD, Professor of Neurology</name_or_title>
      <organization>University of South Florida</organization>
      <phone>813-974-5909</phone>
      <email>tzesiewi@health.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

